Icagen Announces Filing of IND for ICA-105665

Icagen announced that it has filed an investigational new drug application (IND) with the FDA for ICA-105665, a novel small molecule compound for the treatment of epilepsy.

According to Icagen, in preclinical studies, ICA-105665 was active in animal models predictive of efficacy for the treatment of partial seizures, generalized seizures and treatment-resistant seizures. The company added that ICA-105665 has also been shown to have activity in models of neuropathic and inflammatory pain.

Pending FDA approval, Icagen said it plans to initiate a Phase I clinical trial in the third quarter, which will be a double-blind, placebo-controlled study conducted in healthy male volunteers to assess the safety, tolerability and pharmacokinetics of the compound.